Nezodia (Linagliptin)

Linagliptin works by selectively blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, leading to improved blood sugar control.

The appropriate dose of Nezodia is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nezodia, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nezodia (linagliptin) is a once‑daily DPP‑4 inhibitor that does not require dose adjustment in mild to moderate renal impairment, unlike some other agents in the class. Its efficacy in lowering HbA1c is comparable, while its safety profile is similar, with low risk of hypoglycaemia when used alone.

Nezodia tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Nezodia is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events associated with Nezodia include acute pancreatitis, severe hypersensitivity reactions such as rash, angioedema or anaphylaxis, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction, or jaundice.

Nezodia should be avoided in individuals with known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for patients with severe renal impairment, hepatic disease, or a history of pancreatitis, and it should be used only under medical supervision in these populations.